251. AAV-based gene therapy approaches for genetic forms of tauopathies and related neurogenetic disorders.
- Author
-
AL KABBANI, MOHAMED AGHYAD, WUNDERLICH, GILBERT, KÖHLER, CHRISTOPH, and ZEMPEL, HANS
- Subjects
ADENO-associated virus ,GENE therapy ,NEUROGLIA ,NEUROGENETICS ,CEREBRAL amyloid angiopathy - Abstract
Tauopathies comprise a spectrum of genetic and sporadic neurodegenerative diseases mainly characterized by the presence of hyperphosphorylated TAU protein aggregations in neurons or glia. Gene therapy, in particular adeno-associated virus (AAV)-based, is an effective medical approach for difficult-to-treat genetic diseases for which there are no convincing traditional therapies, such as tauopathies. Employing AAV-based gene therapy to treat, in particular, genetic tauopathies has many potential therapeutic benefits, but also drawbacks which need to be addressed in order to successfully and efficiently adapt this still unconventional therapy for the various types of tauopathies. In this Viewpoint, we briefly introduce some potentially treatable tauopathies, classify them according to their etiology, and discuss the potential advantages and possible problems of AAV-based gene therapy. Finally, we outline a future vision for the application of this promising therapeutic approach for genetic and sporadic tauopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF